Home

Novartis, US Political Risks and Investing in Cancer Research

PUBLISHED

2022-03-01

Content

Join John Wylie, Portfolio Manager and Head of Healthcare, as he reviews how Novartis is positioned, provides an overview of the US political risks to the healthcare sector, and addresses how innovation in the prevention of cancer may translate to potential investment profits.

Author